Literature DB >> 21502616

Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Sheryl Zelenitsky1, Noha Alkurdi, Zhanni Weber, Robert Ariano, George Zhanel.   

Abstract

Bacterial killing and the development of reduced vancomycin susceptibility during continuous-infusion vancomycin (CIV) therapy were dependent on the area under the concentration-time curve over 24 h divided by the MIC (ƒAUC(24)/MIC), with values of ≥ 240 (equivalent total serum AUC(24)/MICs of ≥ 480) being bactericidal and suppressing emerging resistance in methicillin-resistant Staphylococcus aureus (MRSA). Also, vancomycin therapy was less likely to be bactericidal and 4.4 times more likely to lead to reduced vancomycin susceptibility in health care-associated MRSA than in community-associated MRSA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502616      PMCID: PMC3122400          DOI: 10.1128/AAC.01472-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

2.  Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections.

Authors:  M Wysocki; F Thomas; M A Wolff; Y Pean; Y Ravaud; B Herman
Journal:  J Antimicrob Chemother       Date:  1995-02       Impact factor: 5.790

Review 3.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

4.  Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.

Authors:  Warren E Rose; Michael J Rybak; Brian T Tsuji; Glenn W Kaatz; George Sakoulas
Journal:  J Antimicrob Chemother       Date:  2007-04-13       Impact factor: 5.790

5.  Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Authors:  George Sakoulas; George M Eliopoulos; Vance G Fowler; Robert C Moellering; Richard P Novick; Natalie Lucindo; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 7.  Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?

Authors:  Jason A Roberts; Jeffrey Lipman; Stijn Blot; Jordi Rello
Journal:  Curr Opin Crit Care       Date:  2008-08       Impact factor: 3.687

8.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

9.  Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.

Authors:  Thomas P Lodise; Ben Lomaestro; Jeffrey Graves; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

10.  Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Pamela A Moise; Davida S Smyth; Nadia El-Fawal; D Ashley Robinson; Patricia N Holden; Alan Forrest; George Sakoulas
Journal:  J Antimicrob Chemother       Date:  2007-11-27       Impact factor: 5.790

View more
  7 in total

Review 1.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

2.  High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.

Authors:  Ilker Uçkay; Louis Bernard; Marta Buzzi; Stephan Harbarth; Patrice François; Elzbieta Huggler; Tristan Ferry; Jacques Schrenzel; Adriana Renzoni; Pierre Vaudaux; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

Review 3.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.

Authors:  Susanna Edith Medellín-Garibay; Silvia Romano-Moreno; Pilar Tejedor-Prado; Noelia Rubio-Álvaro; Aida Rueda-Naharro; Miguel Angel Blasco-Navalpotro; Benito García; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

5.  The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study.

Authors:  Michael Wan; Sandra A N Walker; Elaine Martin; Marion Elligsen; Lesley Palmay; Jerome A Leis
Journal:  BMC Pharmacol Toxicol       Date:  2018-07-31       Impact factor: 2.483

6.  Effect of vancomycin loading dose on clinical outcome in critically ill patients with methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Jin Gu Yoon; Kyungmin Huh; You Min Sohn; Hyo Jung Park; Soo Jin Na; Kyeongman Jeon
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

7.  The Thirty-Day Mortality Rate and Nephrotoxicity Associated With Trough Serum Vancomycin Concentrations During Treatment of Enterococcal Infections: A Propensity Score Matching Analysis.

Authors:  Wasan Katip; Siriporn Okonogi; Peninnah Oberdorfer
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.